Skip to content

13F-HR filed by Flagship Pioneering, LLC

Flagship Pioneering, LLC filed this 13F-HR for the quarter ended 2023-06-30, filed 2023-08-14, with 10 holding rows worth $2,240,750,098.

Accession
0000950123-23-008070
Filed
2023-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2023

A holdings report, 20 entries on the cover page, a total value of $2,240,750,098 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,240,750,098 with VALUE read as dollars as filed, 13F file number 028-17559. The quarter's positions are built on this report. The resolved quarter.

Other managers

  • included managerFlagship Ventures Fund V General Partner LLC 028-18466
  • included managerFlagship Ventures Fund IV General Partner LLC 028-17238
  • included managerNoubar Afeyan 028-19988

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
MODERNA INC60770K107COM12,886,743$1,565,739,275dollars as filed
SANA BIOTECHNOLOGY INC799566104COM33,290,018$198,408,507dollars as filed
OMEGA THERAPEUTICS INC68217N105COMMON STOCK29,225,579$163,663,243dollars as filed
SERES THERAPEUTICS INC81750R102COM23,117,045$110,730,646dollars as filed
FOGHORN THERAPEUTICS INC344174107COMMON STOCK12,674,120$89,225,805dollars as filed
DENALI THERAPEUTICS INC COM24823R105Stock2,619,968$77,315,256dollars as filed
SIGILON THERAPEUTICS INC82657L206cs797,720$17,956,678dollars as filed
EVELO BIOSCIENCES INC299734202COM2,521,369$8,194,452dollars as filed
AXCELLA HEALTH INC05454B105COM29,251,545$6,385,614dollars as filed
SYROS PHARMACEUTICALS INC87184Q206COM NEW993,848$3,130,622dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-23-008070this filing2023-08-14acceptance time not in the bulk data set